Clinical Trial Update: A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of lurbinectedin and durvalumab in participants with extensive-stage small-cell lung cancer, currently no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING